Eduardo Martins

Eduardo Martins

Company: Sagimet Biosciences

Job title: Chief Medical Officer


Breaking New Ground in Targeting Dysfunctional Metabolic Pathways in the Liver: Inhibition of FASN in NASH Patients with the First-in-Class Drug, Denifanstat 4:00 pm

Evaluating the ability of FASN inhibition to improve the key drivers of NASH by: reducing liver fat, inflammation, and fibrosis Validating digital imaging and non-invasive diagnostics as biomarkers of liver injury and predictors of response in clinical trials Exploring initial clinical data in FASCINATE-2, a Phase IIb denifanstat studyRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.